KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | $12.69M | $16.13M | $8.39M |
| Cost of Revenue | N/A | $86.17M | N/A | N/A | $41.29M | $40.19M | $35.02K | $18.24K |
| Gross Profit | N/A | $-86.17M | N/A | N/A | $-41.29M | $-27.50M | $16.09M | $8.38M |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -216.74% | 99.78% | 99.78% |
| Operating Expenses | $188.00M | $54.28M | $110.87M | $96.61M | $16.64M | $13.03M | $45.91M | $27.08M |
| Operating Income | $-188.00M | $-140.44M | $-110.87M | $-96.61M | $-57.92M | $-40.53M | $-29.82M | $-18.70M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -319.41% | -184.91% | -222.84% |
| Net Income | $-183.44M | $-126.64M | $-92.91M | $-82.34M | $-46.24M | $-29.12M | $-20.82M | $-15.80M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -229.44% | -129.08% | -188.29% |
| EPS (Basic) | $-3.69 | $-3.44 | $-3.33 | $-3.36 | $-2.33 | $-1.64 | $-1.38 | $-1.53 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |